Patent US5354549A successfully refreshed from Google Patents.
US5354549A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Iodinated esters
Assignee: AMERHSAM HEALTH
•
Filing: 1991-12-05
•
Granted: 1994-10-11
•
Expires: 2011-12-05
Abstract
Abstract The invention relates to metabolically labile water-insoluble esters of formula (I), wherein R 1 is an aliphatic, araliphatic, aryl or heterocyclic group; R 2 is hydrogen or an aliphatic, aryl or araliphatic group; R 3 is as defined for R 1 , or R 3 and R 2 together form an alkylene chain; the molecule containing at least one iodine atom and being metabolised to form products which are soluble in body fluids. The esters are used in X-ray and ultrasound image enhancement.
Inventors
- 👤 Jo Klaveness
- 👤 Per Strande
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:50
CPC Classifications
C; C07; C07D; C07D333/00; C07D333/02; C07D333/04; C07D333/26; C07D333/38
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
183 words
An injectable contrast medium having a reduced tendency to cause lung era boll following intravascular administration to a human or non-human animal subject of an X-ray or ultrasound image enhancing amount of the medium, wherein the medium comprises a water-insoluble iodinated ester of the formula (I): ##STR2## in which R 1 is a substituted or unsubstituted C 1-20 aliphatic, C 7-20 -araliphatic or C 6-20 aryl group or a C 1-20 heterocyclic group having one or more hetero atoms selected from O, S and N; R 2 is hydrogen or a substituted or unsubstituted aliphatic, aryl or araliphatic group; and R 3 is as defined above for R 1 , and may be the same as or different from R 1 ; or R 2 and R 3 together represent a substituted or unsubstituted C 1-4 alkylene group, the molecule containing at least one iodine atom and being metabolizable to products which are soluble in body fluids; said ester being in particulate form in suspension in a liquid for injection and having a mean particle size within the range 0.01 to 3 microns.
Claim 2
Dependent Claim
183 words
An injectable contrast medium having a reduced tendency to cause lung era boll following intravascular administration to a human or non-human animal subject of an X-ray or ultrasound image enhancing amount of the medium, wherein the medium comprises a water-insoluble iodinated ester of the formula (I): ##STR2## in which R 1 is a substituted or unsubstituted C 1-20 aliphatic, C 7-20 -araliphatic or C 6-20 aryl group or a C 1-20 heterocyclic group having one or more hetero atoms selected from O, S and N; R 2 is hydrogen or a substituted or unsubstituted aliphatic, aryl or araliphatic group; and R 3 is as defined above for R 1 , and may be the same as or different from R 1 ; or R 2 and R 3 together represent a substituted or unsubstituted C 1-4 alkylene group, the molecule containing at least one iodine atom and being metabolizable to products which are soluble in body fluids; said ester being in particulate form in suspension in a liquid for injection and having a mean particle size within the range 0.01 to 3 microns.
Claim 3
Dependent Claim
24 words
An medium as claimed in claim 1 wherein, in the compound of formula I, R 1 and/or R 3 is an iodinated phenyl group.
Claim 4
Dependent Claim
17 words
An medium as claimed in claim 2 wherein R 1 and/or R 3 is an triiodophenyl group.
Claim 5
Dependent Claim
33 words
A process for the preparation of a medium as claimed in claim 1 comprising precipitation of the compound of formula (I) from solution in a water-miscible solvent by admixture with water, with agitation.
Claim 6
Dependent Claim
38 words
A process for the preparation of a medium as claimed in claim 1 comprising the steps of (i) mechanically crushing the solid compound of formula (I); and (ii) suspending the resulting particulate compound in a liquid for injection.
Claim 7
Independent Claim
217 words
A method of enhancing an X-ray or ultrasound image of the liver and/or spleen of a human or non-human animal subject comprising the intravascular administration to the subject of an X-ray or ultrasound image enhancing amount of an injectable contrast medium, wherein the subject is at risk of developing lung emboli following said administration, the improvement comprising reducing the risk of developing lung emboli following administration of the medium, which medium comprises a water-insoluble iodinated ester of the formula (I) ##STR3## in which R 1 is a substituted or unsubstituted C 1-20 aliphatic, C 7-20 -araliphatic or C 6-20 aryl group or a C 1-20 heterocyclic group having one or more hetero atoms selected from O, S and N; R 2 is hydrogen or a substituted or unsubstituted aliphatic, aryl or araliphatic group; and R 3 is as defined above for R 1 , and may be the same as or different from R 1 ; or R 2 and R 3 together represent a substituted or unsubstituted C 1-4 alkylene group, the molecule containing at least one iodine atom and being metabolizable to products which are soluble in body fluids; said ester being in particulate form in suspension in a liquid for injection and having a mean particle size within the range 0.01 to 3 microns.
Claim 8
Independent Claim
217 words
A method of enhancing an X-ray or ultrasound image of the liver and/or spleen of a human or non-human animal subject comprising the intravascular administration to the subject of an X-ray or ultrasound image enhancing amount of an injectable contrast medium, wherein the subject is at risk of developing lung emboli following said administration, the improvement comprising reducing the risk of developing lung emboli following administration of the medium, which medium comprises a water-insoluble iodinated ester of the formula (I) ##STR3## in which R 1 is a substituted or unsubstituted C 1-20 aliphatic, C 7-20 -araliphatic or C 6-20 aryl group or a C 1-20 heterocyclic group having one or more hetero atoms selected from O, S and N; R 2 is hydrogen or a substituted or unsubstituted aliphatic, aryl or araliphatic group; and R 3 is as defined above for R 1 , and may be the same as or different from R 1 ; or R 2 and R 3 together represent a substituted or unsubstituted C 1-4 alkylene group, the molecule containing at least one iodine atom and being metabolizable to products which are soluble in body fluids; said ester being in particulate form in suspension in a liquid for injection and having a mean particle size within the range 0.01 to 3 microns.
Claim 9
Dependent Claim
15 words
A medium as claimed in claim 1 wherein the compound of formula (I) is Pivaloyloxymethyl-5-(N-acetylamino)-3-(N-acetyI-N-methylamino)-2,4,6-triiodobenzenecarboxylate.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-10-10 | 1998-04-11 | 1998-10-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-10-10 | 2002-04-11 | 2002-10-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-10-10 | 2006-04-11 | 2006-10-11 | $7700.00 | Window Closed / Lapsed |